Literature DB >> 1413835

Hürthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior.

M F Herrera1, I D Hay, P S Wu, J R Goellner, J J Ryan, J R Ebersold, E J Bergstralh, C S Grant.   

Abstract

The latest World Health Organization International Classification defines papillary thyroid carcinoma by its "follicular cell differentiation...as well as characteristic nuclear changes". However the oxyphilic (Hürthle cell) papillary carcinoma have nuclei which generally resemble the nuclei seen in oxyphilic follicular carcinomas, and such oxyphilic papillary tumors may behave more aggressively than typical papillary cancers. To further characterize these rare tumors, we identified during a 32-year period 22 patients with oxyphilic papillary cancer and compared them with 1,084 patients with typical papillary cancers and 57 patients with oxyphilic follicular cancers treated by the Mayo surgical group during the same time period. Although typical papillary and oxyphilic papillary cancers were comparable with regards to patient age, tumor size and extent, TNM stage, and prognostic score (AGES), there were significant differences. Compared to typical papillary tumors, oxyphilic papillary cancers had fewer neck nodal metastases at primary diagnosis (5% vs 40%, p less than 0.0001), were more often DNA non-diploid (71% vs 21%, p less than 0.001), and after 10 postoperative years had higher rates of both tumor recurrence (28% vs 11%, p less than 0.0001) and cause-specific mortality (1.7% vs 4%, p less than 0.0005). In these four important respects the oxyphilic papillary cancers more resembled the oxyphilic follicular cancers. For oxyphilic follicular cancers, the frequency of initial neck nodal metastases was 7% (cf 5%); 83% of the oxyphilic follicular tumors were non-diploid (cf 71%), and at 10 years postoperatively the tumor recurrence and cause-specific mortality rates were 28% and 18%, insignificantly different from 28% and 17% seen with the oxyphilic papillary cancers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1413835     DOI: 10.1007/bf02067351

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  20 in total

1.  Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period.

Authors:  L B WOOLNER; O H BEAHRS; B M BLACK; W M McCONAHEY; F R KEATING
Journal:  Am J Surg       Date:  1961-09       Impact factor: 2.565

2.  Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid.

Authors:  J J Ryan; I D Hay; C S Grant; L M Rainwater; G M Farrow; J R Goellner
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

Review 3.  Papillary thyroid carcinoma: factors influencing prognosis and current therapy.

Authors:  E L Mazzaferri
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

4.  Prognostic value of nuclear DNA content in papillary thyroid carcinoma.

Authors:  K Cohn; M Bäckdahl; G Forsslund; G Auer; G Lundell; T Löwhagen; E Tallroth; J S Willems; A Zetterberg; P O Granberg
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

5.  Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study.

Authors:  M A Sobrinho-Simões; J M Nesland; R Holm; M C Sambade; J V Johannessen
Journal:  Ultrastruct Pathol       Date:  1985       Impact factor: 1.094

6.  Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system.

Authors:  I D Hay; C S Grant; W F Taylor; W M McConahey
Journal:  Surgery       Date:  1987-12       Impact factor: 3.982

7.  Hürthle cell and mitochondrion-rich cell tumors. A clinicopathologic study.

Authors:  R González-Cámpora; A Herrero-Zapatero; E Lerma; F Sanchez; H Galera
Journal:  Cancer       Date:  1986-03-15       Impact factor: 6.860

8.  Mortality from papillary thyroid carcinoma. A case-control study of 56 lethal cases.

Authors:  S A Smith; I D Hay; J R Goellner; J J Ryan; W M McConahey
Journal:  Cancer       Date:  1988-10-01       Impact factor: 6.860

9.  Papillary thyroid carcinomas. Morphology and prognosis.

Authors:  J Tscholl-Ducommun; C E Hedinger
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  14 in total

Review 1.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.

Authors:  Eleonore Fröhlich; Inge Fink; Richard Wahl
Journal:  Invest New Drugs       Date:  2008-09-20       Impact factor: 3.850

Review 3.  Hurthle Cell Lesion: Controversies, Challenges, and Debates.

Authors:  Michael Shawky; Mahmoud Sakr
Journal:  Indian J Surg       Date:  2015-10-30       Impact factor: 0.656

4.  Understanding Malignancies of the Thyroid Gland: Institutional Experience.

Authors:  Jaimanti Bakshi; Sourabha Kumar Patro; Navjot Kaur; Naresh Kumar Panda; Grace Budhiraja
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-09-05

Review 5.  Papillary thyroid carcinoma variants.

Authors:  Ricardo V Lloyd; Darya Buehler; Elham Khanafshar
Journal:  Head Neck Pathol       Date:  2011-01-08

6.  Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.

Authors:  Vera Wenter; Annamirl Jellinek; Marcus Unterrainer; Freba Ahmaddy; Sebastian Lehner; Nathalie Lisa Albert; Peter Bartenstein; Thomas Knösel; Christine Spitzweg; Harun Ilhan; Andrei Todica
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

7.  Hurthle cell carcinoma arising from thyroid papillary carcinoma.

Authors:  L Jonathan Zwi; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

8.  Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.

Authors:  Eleonore Fröhlich; Peter Brossart; Richard Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-24       Impact factor: 9.236

Review 9.  Hürthle cell carcinoma.

Authors:  E Yutan; O H Clark
Journal:  Curr Treat Options Oncol       Date:  2001-08

Review 10.  My approach to oncocytic tumours of the thyroid.

Authors:  S L Asa
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.